Found this article that pretty much covers what we already know. But it had interesting followup perspectives by CML doctors. The first perspective is actually my doctor and pretty much follows what he has told me in the past. He believes cessation should only be in clinical trials. But his T-Cell opinions are very interesting. I wonder if they look at T-Cells in any of the cessation trials? It would be interesting to know if the patients that relapsed had low T-Cells.
The second perspective is what interested me because they actually define what Deep Molecular Response (DMR) is. They consider 0.0069% (IS) or less to be DMR. Which is frustrating for me as I have been at 0.01% or 0.02% for a year now. I just can't seem to get lower. But it is even more frustrating because my lab won't report on anything less than 0,01% unless it is undetected. The one jump I had to 0.02% in my opinion means it is unlikely I am less than 0.01%. I understand why they won't report less than 0.01% but as a patient it just frustrates me.
http://www.healio.co...tinue-dasatinib